The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
 
Joseph J Zhao
No Relationships to Disclose
 
Khi Yung Fong
No Relationships to Disclose
 
Yiong Huak Chan
No Relationships to Disclose
 
Jeremy Chee Seong Tey
No Relationships to Disclose
 
Shaheenah S. Dawood
Honoraria - Abbvie; AstraZeneca; biocon; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Janssen-Cilag; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - MSD Oncology
Speakers' Bureau - AstraZeneca; Pfizer; Roche/Genentech
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer; Roche
 
Soo-Chin Lee
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; MSD Oncology; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; MSD Oncology; Novartis; Pfizer; Roche; Sanofi
Research Funding - ASLAN Pharmaceuticals; Bayer; Eisai; Epizyme; Karyopharm Therapeutics; Pfizer; Taiho Pharmaceutical
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ACT Genomics; Novartis; Pfizer; Roche
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Raghav Sundar
Stock and Other Ownership Interests - Teladoc
Honoraria - AstraZeneca; Bristol-Myers Squibb; DKSH; Ipsen; Lilly; MSD; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; DKSH; Eisai; GlaxoSmithKline; Merck; MSD; Novartis; Taiho Pharmaceutical
Research Funding - MSD; Natera; Paxman
Travel, Accommodations, Expenses - AstraZeneca; DKSH; Eisai; Roche; Taiho Pharmaceutical
 
Joline SJ Lim
Honoraria - AstraZeneca; DKSH; Eisai; MSD; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - AstraZeneca; DKSH; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; MSD